Pfizer's Novel Antibiotic Xifunuo® (Aztreonam-Avibactam) Approved in China for Multidrug-Resistant Gram-Negative Infections

Smart Finance APP learned that Pfizer Inc. (PFE.US) announced today (June 30) that the new antibacterial drug Zaviflo® (Aztreonam-Avibactam Sodium for Injection, hereinafter referred to as "Aztreonam/Avibactam") has been officially approved by the National Medical Products Administration for the treatment of complicated intra-abdominal infections (cIAI) in adults caused by Gram-negative bacteria with limited or no alternative treatment options, hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP).

Cefnol® is the first β-lactam antibiotic/β-lactamase inhibitor combination formulation capable of covering all CRE enzyme types. Through a fixed combination design, Cefnol® not only covers KPC and OXA-48 carbapenemases but also effectively targets MBL-producing bacteria, overcoming the limitation of previous β-lactamase inhibitor combinations that could not cover MBL. It exhibits broad-spectrum enzyme inhibitory activity, improving patient treatment outcomes while reducing the risk of resistance. This approval helps further curb the trend of bacterial resistance, enhances the precise coverage of new antibacterial drugs for infections caused by all CRE enzyme types, and advances antimicrobial therapy into a new era of precision treatment, which is of great significance for public health and innovative treatment paradigms.

Jean-Christophe Pointeau, President of Pfizer China and Chairman of the RDPAC Executive Committee, stated: "Antimicrobial resistance is a common challenge faced worldwide. Pfizer has been deeply committed to the anti-infective field for many years, consistently focusing on the research and development of innovative anti-infective drugs to assist clinicians in addressing drug-resistant bacterial infections and safeguarding life and health. The recent approval of Zavicefta® will once again expand the treatment options for carbapenem-resistant Gram-negative bacteria (CRO), providing an innovative targeted therapy solution for clinical practice, helping more infected patients benefit clinically, and curbing the further development of resistance trends. We thank the National Medical Products Administration and other relevant departments for their support of new antibacterial drugs. Pfizer will continue to address the health challenges brought by antimicrobial resistance, steadfastly fulfilling our mission to 'Bring breakthrough innovations that change patients' lives.'"